Centessa Pharmaceuticals plc (CNTA)
NASDAQ: CNTA · Real-Time Price · USD
22.35
-0.17 (-0.75%)
Nov 6, 2025, 9:40 AM EST - Market open
Centessa Pharmaceuticals Stock Forecast
Stock Price Forecast
The 8 analysts that cover Centessa Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $31.75, which forecasts a 42.06% increase in the stock price over the next year. The lowest target is $27 and the highest is $38.
Price Target: $31.75 (+42.06%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Centessa Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 7 | 7 | 7 | 5 | 5 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 11 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stephens & Co. | Stephens & Co. | Buy Initiates $35 | Buy | Initiates | $35 | +56.60% | Oct 28, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates $28 | Strong Buy | Reiterates | $28 | +25.28% | Oct 6, 2025 |
| Wells Fargo | Wells Fargo | Buy Initiates $31 | Buy | Initiates | $31 | +38.70% | Sep 3, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $30 | Strong Buy | Maintains | $30 | +34.23% | Aug 12, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $30 | Strong Buy | Maintains | $30 | +34.23% | Jul 30, 2025 |
Financial Forecast
Revenue This Year
16.85M
Revenue Next Year
3.14M
from 16.85M
Decreased by -81.36%
EPS This Year
-1.39
from -2.06
EPS Next Year
-1.66
from -1.39
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 34.9M | 35.6M | |||
| Avg | 16.8M | 3.1M | |||
| Low | 14.7M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 111.1% | |||
| Avg | - | -81.4% | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.26 | -1.43 | |||
| Avg | -1.39 | -1.66 | |||
| Low | -1.47 | -1.99 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.